GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

nitroxoline   Click here for help

GtoPdb Ligand ID: 13964

Synonyms: APL-1202 | APL1202 | compound 10 [PMID: 30939017]
Approved drug PDB Ligand
nitroxoline is an approved drug
Compound class: Synthetic organic
Comment: Nitroxoline is an antimicrobial used to treat urinary tract infections [3]. Repurposing of nitroxoline for infectious diseases and oncological indications has been proposed, although pharmacokinetic challenges are likely to hamper clinical translation.

From a patent it would appear that Healx Ltd. are interested in pursuing nitroxoline for the treatment of plexiform neurofibroma/neurofibromatosis type 1 (NF1) [1]. Review of Healx's active pipeline (January 2026) reveals two candidates with codes HLX-1502 and HLX-0213 in development for NF1 [4]. HLX-1502 has reached phase 2 whereas HLX-0213 is in the discovery phase (at time of writing), so it is plausible that HLX-1502 is nitroxoline. We await formal disclosure of this potential association.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 75.73
Molecular weight 190.16
XLogP 0.8
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CN=C2C(=C1)C(=CC=C2O)[N+](=O)[O-]
Isomeric SMILES C1=CC2=C(C=CC(=C2N=C1)O)[N+](=O)[O-]
InChI InChI=1S/C9H6N2O3/c12-8-4-3-7(11(13)14)6-2-1-5-10-9(6)8/h1-5,12H
InChI Key RJIWZDNTCBHXAL-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Brown D. (2025)
Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma.
Patent number: US20250000852A1. Assignee: Healx Ltd. Priority date: 18/11/2022. Publication date: 02/01/2025.
2. Deng Y, Wu L, Pan K. (2020)
Nitroxoline prodrug and use thereof.
Patent number: CA3113463A1. Assignee: Jiangsu Yahong Meditech Co Ltd. Priority date: 27/09/2019. Publication date: 02/04/2020.
3. FUSON RC, BAUMAN RA et al.. (1947)
The synthesis of 5-hydroxy-8-nitroquinoline and certain of its derivatives.
J Org Chem, 12 (6): 799-806. [PMID:18919732]
4. Healx. 
Pipeline.
Accessed on 19/01/2026. Modified on 19/01/2026. https://healx.ai, https://healx.ai/pipeline/
5. Heinrich T, Seenisamy J, Blume B, Bomke J, Calderini M, Eckert U, Friese-Hamim M, Kohl R, Lehmann M, Leuthner B et al.. (2019)
Discovery and Structure-Based Optimization of Next-Generation Reversible Methionine Aminopeptidase-2 (MetAP-2) Inhibitors.
J Med Chem, 62 (10): 5025-5039. [PMID:30939017]
6. Liu JO, Shim JS, Chong CR, Bhat S. (2014)
Quinoline compounds as inhibitors of angiogenesis, human methionyl aminopeptidase, and SIRT1, and methods of treating disorders.
Patent number: US8729097B2. Assignee: Johns Hopkins University. Priority date: 06/10/2009. Publication date: 20/05/2014.